ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,751.13
0.97%
US Tech 100
19,572.00
0.00%
Dow Jones
42,080.37
0.30%
Brent Oil
77.62
0.36%
Bitcoin
62,248.00
0.19%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. NeuroSense Therapeutics Ltd (NRSN) Quote

NeuroSense Therapeutics Ltd

NeuroSense Therapeutics Ltd (NRSN)

NASDAQ
1.22
0.00
(0.00%)
Closed October 09 4:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
1.22
Bid
1.22
Ask
1.29
Volume
-
0.00 Day's Range 0.00
0.40 52 Week Range 2.33
Previous Close
1.22
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
307,997
Financial Volume
-
VWAP
-

Ask ADVFN Intelligence (AI)

NRSN Latest News

More News

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting PR Newswire CAMBRIDGE, Mass., Oct. 7, 2024 CAMBRIDGE, Mass., Oct. 7, 2024 /PRNewswire/...

October 07 2024
PR Newswire (US)

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's PR Newswire CAMBRIDGE, Mass., Sept. 24, 2024 The Company's intellectual...

September 24 2024
PR Newswire (US)

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule PR Newswire CAMBRIDGE, Mass., Sept. 24, 2024 CAMBRIDGE, Mass., Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics...

September 24 2024
PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

August 30 2024
Edgar (US Regulatory)

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire CAMBRIDGE, Mass., Aug. 30, 2024 CAMBRIDGE, Mass., Aug. 30, 2024 /PRNewswire/ -- NeuroSense...

August 30 2024
PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

August 28 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

August 26 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

August 16 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

August 16 2024
Edgar (US Regulatory)

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price PR Newswire CAMBRIDGE, Mass., Aug. 7, 2024 CAMBRIDGE, Mass., Aug. 7, 2024...

August 07 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.021.666666666671.21.291.2453031.23737993CS
40.076.086956521741.151.4550.91633591.27201022CS
120.3946.98795180720.831.4550.5123079970.86370569CS
26-0.64-34.40860215051.861.9290.5122545851.00032314CS
520.6119100.6248972210.60812.330.44142851.07300722CS
156-3.33-73.18681318684.558.180.410290713.44316804CS
260-3.33-73.18681318684.558.180.410290713.44316804CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
$ 11.92
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.2859
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.95
(0.00%)
0
AACGATA Creativity Global
$ 0.8692
(0.00%)
0
AALAmerican Airlines Group Inc
$ 11.92
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.2859
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.95
(0.00%)
0
AACGATA Creativity Global
$ 0.8692
(0.00%)
0
AALAmerican Airlines Group Inc
$ 11.92
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.2859
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.95
(0.00%)
0
AACGATA Creativity Global
$ 0.8692
(0.00%)
0

NRSN Discussion

View Posts
runncoach runncoach 1 month ago
From this evening's 6K. No idea if it's BS or not.
NeuroSense Therapeutics Ltd. (the Company) hereby reports that it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership for the development and commercialization of its lead drug candidate, PrimeC, for the treatment of Amyotrophic Lateral Sclerosis (ALS).



These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments and royalty payments as part of an agreement. NeuroSense anticipates receiving terms from these discussions in Q4 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what would be the final terms, if any, or that a definitive agreement will be reached.
👍️0
runncoach runncoach 2 months ago
Money raise with .75 warrants attached fyi. Now we know why the price has remained so low IMO
👍️0
vein vein 3 months ago
Thanks much for the insight !
👍️0
runncoach runncoach 3 months ago
Who knows? Unless you are trading the stock, real results are a long ways off IMO and that can lead to opportunity cost. If it's a small percentage of a speculative portfolio the current price probably isn't bad. Just depends on your patience level
👍️0
vein vein 3 months ago
Why the sell off ?? Thanks in advance!
👍️0
vein vein 3 months ago
Seems like a decent entry ?
👍️0
runncoach runncoach 3 months ago
The data is good but they'll have to raise money for a P3 so these guys are still a ways off IMO. They've mentioned a potential Biogen partnership last year yet here we stand. I do believe the drug is safe and has a real chance. Timing is everything.
👍️0
vein vein 3 months ago
Time to buy now ??? Newbie here! Any thoughts ??
👍️0
Monksdream Monksdream 3 months ago
NRSN under $2
👍️0
runncoach runncoach 3 months ago
Great data out. On to P3. Only thing that will likely sustain share price after this rally is partnership IMO.
👍️0
Awl416 Awl416 3 months ago
Don’t blink
👍️0
runncoach runncoach 5 months ago
Certainly showing a positive trend on the scientific front.
https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/93791685/neurosense-announces-new-positive-data-analysis-fr
👍️0
runncoach runncoach 6 months ago
Financing broke the stock for now. Either Biogen news or dead money IMO
👍️0
runncoach runncoach 6 months ago
Looks like there will be a data presentation on the sixteenth at a conference. Back in for a gamble at 1.70.
👍️0
runncoach runncoach 6 months ago
And there's the money raise at 1.50
👍️0
runncoach runncoach 6 months ago
Sold at 2.12. Only update today on the additional biomarker data was talking about peer reviews and conferences. I expected data at least a month ago. I'm concerned they'll raise money before we get any significant data updates. I could be making a mistake but taking profits from .79 so can't be too upset if I do. I'll buy back if it goes lower most likely. GLTA
👍️0
glenn1919 glenn1919 7 months ago
NRSN..........................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 7 months ago
NRSN under $2
👍️0
runncoach runncoach 7 months ago
I like Coya a lot as well. I was hoping to see how the Biogen data plays out here and then moving funds there. Hopefully I'll get that chance. I'm not sure COYA's next coming data will be ideal based on the dosage and other trial parameters but could give a great indication to set up a pivotal P3. Lot of bigger money over there. I've got my eyes on them for sure. JMHO
👍️0
FooBarAndGrill FooBarAndGrill 7 months ago
Suggest a look at $COYA for ALS.
👍️0
runncoach runncoach 7 months ago
Disappointed for the ALS community. Hoping NRSN can provide some hope.
https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-topline-results-120000695.html?guccounter=1&guce_referrer=YW5kcm9pZC1hcHA6Ly9jb20uZ29vZ2xlLmFuZHJvaWQuZ29vZ2xlcXVpY2tzZWFyY2hib3gv&guce_referrer_sig=AQAAAAM8h3Ee_7hkwe__ixrWmntWVPdxe8WZ1ZpxVn7ZSc5Y_cvU8dUOeH8gNnkII0GDb_rsadt-ieRtojdTcEbDoBluMPdmwoVEaO7k8HMPi6OgMQhLipitwShkj668qEiwBreTeVNkxishXrsTPgOOOMTmvMybqLk3QVA9AiTxt2Bt
👍️0
runncoach runncoach 7 months ago
If Biogen results are good then yes. If not then no lol. It's a gamble. I'm not buying at these levels but my cost basis is .795 so I don't have to.
👍️0
BurgerKing82 BurgerKing82 7 months ago
Is it good time to buy ?
👍️0
Monksdream Monksdream 7 months ago
NRSN new 52 week high
👍️0
glenn1919 glenn1919 7 months ago
NRSN.................................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 months ago
NRSN........................................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783
👍️0
runncoach runncoach 7 months ago
I don't know about the biomarker data or any partnership discussions are going but this sure is a lot of volume in a positive fashion the last couple days.
👍️0
runncoach runncoach 8 months ago
Updated slide presentation fyi
https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/93337353/form-6-k-report-of-foreign-issuer-rules-13a-16
👍️0
runncoach runncoach 8 months ago
Looks like additional good news today but the neurofilament results we have been imminently expecting are on track for some time this quarter, which could mean another 5 or 6 weeks. The question remains of how good those results are (or aren't) and if the company raises money before or after. JMHO
👍️0
Awl416 Awl416 8 months ago
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
👍️0
Monksdream Monksdream 8 months ago
NRSN under $2
👍️0
BurgerKing82 BurgerKing82 8 months ago
Tues is the 20th I think....Any day.now?...tick tock....
👍️0
runncoach runncoach 8 months ago
Looks like the neurofilament light data in collaboration with Biogen isn't quite imminent as today's PR says the coming weeks fyi.
👍️0
runncoach runncoach 8 months ago
Looks like the company has regained full Nasdaq compliance
👍️0
BurgerKing82 BurgerKing82 8 months ago
Could be tomorrow lol
👍️0
runncoach runncoach 8 months ago
Not sure the holdup on the neurofilament light data. Though it was supposed to be out in January
👍️0
rouge Vaughn rouge Vaughn 8 months ago
yeah looking forward to 2 dollars and up with volume and news
👍️0
runncoach runncoach 8 months ago
Quite a run today. Fingers crossed on the new data when released
👍️0
runncoach runncoach 8 months ago
Only what you can afford to lose. As risky as any.
👍️0
BurgerKing82 BurgerKing82 8 months ago
How many shares do folks have in here...I was thinking of getting a few
👍️0
BurgerKing82 BurgerKing82 8 months ago
Sounds Rational...In 6/22 it did a little more than 3x on 220 million shares...In December it tripled on much smaller volume...Then again in 6/22 ,I guess it could have went a lot higher in pre- mkt/after-hours,maybe that kinda explains the huge volume....idk seems to have potential for a good rip
👍️0
runncoach runncoach 8 months ago
I don't honestly know. It's seen huge profit taking every time they've put out positive news. Traders/shorters, who knows. The company needs money to advance and when that's the case you see wild swings. The ball is in Biogen's court it would seem. All depends on the biomarker results we should get at any time.
👍️0
BurgerKing82 BurgerKing82 8 months ago
hey Runn....What caused Nrsn to dip.between Dec 4th-6th...just curious
👍️0
BurgerKing82 BurgerKing82 9 months ago
Supposedly they are fully funded into Q2 24'.....As of October 4....There was 22-26 million shares that went buy as the share price declined a bit in December...Maybe it's nothing..."We are optimistic about our mechanisms of action... anticipated in Q4 of 23'".......Still kinda interested


..
👍️0
BurgerKing82 BurgerKing82 9 months ago
This ticker looked pretty attractive until I noticed it was an Israeli one... Similar to Chinese, Israeli ones more often than not....Is it worth setting that factor aside?
👍️0
runncoach runncoach 9 months ago
Potentially yes as long as some of the biomarker data is good. We should find out about that data in the next week or two supposedly to the best of my understanding.
👍️0
BurgerKing82 BurgerKing82 9 months ago
Is there a positive Catalyst Coming later this month?
👍️0
rouge Vaughn rouge Vaughn 10 months ago
you choice is display picture is what is in question, here why are you using that image
👍️0
rakp rakp 10 months ago
Why this sudden reversal?
👍️0
Invest-in-America Invest-in-America 10 months ago
NRSN: How many time must I post this??? READ IT. I quoted the figures ACCURATELY. In any event, this JUNK STOCK is dead!! Let's all MOVE ON!!

https://www.google.com/search?q=is+als+a+rare+disease&sca_esv=588105669&source=hp&ei=an9vZdOZGevHkPIP2rCN8Aw&iflsig=AO6bgOgAAAAAZW-Nem49qIuR5YltejA1r0lBYMi_4ZKE&oq=is+als+a+ra&gs_lp=Egdnd3Mtd2l6IgtpcyBhbHMgYSByYSoCCAAyBRAAGIAEMgYQABgWGB4yCxAAGIAEGIoFGIYDMgsQABiABBiKBRiGA0iRL1AAWJ4YcAB4AJABAJgB0wKgAY4KqgEHNy4yLjEuMbgBAcgBAPgBAcICCxAAGIAEGLEDGIMBwgIOEC4YgAQYsQMYxwEY0QPCAgsQLhiABBjHARjRA8ICBRAuGIAEwgIREC4YgAQYsQMYgwEYxwEY0QPCAggQLhiABBixA8ICCBAAGIAEGLEDwgILEC4YxwEY0QMYgATCAg4QABiABBiKBRixAxiDAcICCxAuGIAEGLEDGIMBwgIXEC4YgAQYsQMYlwUY3AQY3gQY4ATYAQG6BgYIARABGBQ&sclient=gws-wiz
👍️0

Your Recent History

NASDAQ
NRSN
NeuroSense Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved